ACM Biolabs appoints David Lawrence to its Board as Non-Executive Director

– SINGAPORE, Singapore –  ACM Biolabs (EPA: ALSEN) a pioneering Singaporean-Swiss biotechnology company, which specializes in the development of targeted therapeutics for the prevention of multiple life-threatening diseases based on its proprietary ACM tunable polymer-based delivery ATP™ technology, today announced the appointment of David Lawrence to its Board as a Non-Executive Director.…